Galit Frydman Discusses JTH Research on Cerebral Vein Thrombosis Risk from Hormonal Contraceptives
Galit Frydman, Founder and Chief Scientific Officer of Coagulo Medical Technologies, Inc., reposted from Journal of Thrombosis and Haemostasis (JTH) on LinkedIn:
“Yet another example of how femtech needs more attention. Hormonal birth control is such a popular form of birth control, yet it can pose life-threatening adverse events to the woman using it.
I never realized how much women’s, maternal and fetal medicine was behind until I had my own pregnancy and child.
The market size is not a question here….why is funding and why are companies so far behind on these issues? (lots of reasons for this! but I thought it would start an interesting conversation on this platform)”
Journal of Thrombosis and Haemostasis (JTH) has shared a post on LinkedIn:
“The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
In this case-control study of 206 women with CVT and 868 controls, combined hormonal contraceptive (CHC) use was associated with a 10-fold higher risk of CVT. Risk increased with higher estrogen doses and was particularly elevated with fourth-generation pills (OR 28.3). Progestin-only and variable-dose CHCs carried a 6-fold increased risk. Importantly, thrombophilia and positive family history had synergistic effects, with odds ratios exceeding 200 in some subgroups.”
Title: The risk of cerebral vein thrombosis associated with different types of combined hormonal contraceptives: a case-control study
Authors: Maria Abbattista, Addolorata Truma, Ida Martinelli, Francesca Gianniello, Serena M. Passamonti, Marco Capecchi, Andrea Artoni, Flora Peyvandi, Paolo Bucciarelli
Read the full article here.
Stay updated with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals